Home/Therapeutics/Infectious disease & vaccines
Infectious Disease and Vaccine Medical Writing and Evidence Synthesis
Pubrica supports sponsors and research teams in infectious disease and vaccines with medical writing, statistical analysis and evidence synthesis. Typical projects include efficacy and effectiveness trials, immunogenicity studies, transmission modelling and post-authorisation surveillance. We prepare protocols, analysis plans, clinical study reports, systematic reviews and publications reported to CONSORT 2025, STROBE and GRADE, with clear reporting of whether immunological endpoints are supported as correlates of protection. A designated project lead coordinates the protocol, statistical analysis plan, clinical study report and publications to keep data interpretation and messaging consistent.
The reporting guideline and extension depend on your study design. We confirm them during the free scoping read.
- Writers matched to the therapy area
- One designated project lead
- Reporting guideline confirmed
- Mutual NDA on request
- You remain the sponsor
Therapy Area Scope
Infectious disease and vaccine study types, standards and endpoints
Each therapy area has its own typical study designs, reporting guidelines and endpoint questions. We assign a lead who has worked in infectious disease and vaccines, so documents follow the right standards from the start.
Study types
Typical study types
Efficacy and effectiveness trials, immunogenicity studies, transmission modelling and post-authorisation surveillance.
Reporting standards
Guidelines we apply
CONSORT 2025; STROBE for observational effectiveness; GRADE for synthesis; modelling reported to a transparent standard.
Key endpoint question
What reviewers examine closely
Correlates of protection: whether an immunological endpoint can substitute for clinical efficacy, and what evidence supports this.
Common Review Points
Common review points in infectious disease and vaccine submissions
These are issues that reviewers and payers often raise in infectious disease and vaccines. We check for them while preparing documents so they can be addressed before submission.
Points we check
Our Services
Services for infectious disease and vaccine programmes
Services are grouped by programme stage. Device and diagnostic work is governed by MDR and IVDR rather than ICH and is covered on the relevant sector pages.
59 services, grouped by programme stage
Services can be commissioned individually or as a programme. A designated project lead coordinates the documents to keep data interpretation and messaging consistent.
Who we serve
Who we support in infectious disease and vaccines
We work with sponsor teams and clinical investigators across these functions.
Teams we work with
Our compliance and guideline standards
Guidelines and standards for infectious disease and vaccine documents
Each document is written to the guideline and extension your study design requires. We record the edition applied and check that it is the current one.
Applicable standards
Use of AI Tools
AI tools support search and formatting, not scientific writing
This policy applies to every therapy area and every project timeline.
Our AI policy
How it works
Our five-step process, starting with a free scoping read
We review your programme before we provide a quote.
One
Scoping read
Free, within two business days. We assess what the programme needs, who would lead it and the likely cost.
Two
Project lead assigned
A lead who has worked in the therapy area is assigned before work starts and stays with the project throughout.
Three
Outline approval
You approve each section and its sources before drafting begins.
Four
Draft and review
Each draft goes through independent review, quality control and reference verification, each signed off separately.
Five
Handover
You receive the deliverable with its working material. Revisions are included within the agreed scope.
After
Follow-up questions
Questions on a document are answered by the writer who prepared it.
Our experts
The team for infectious disease and vaccine projects
Writers are assigned by therapy area, not by availability. They hold a master’s degree or doctorate in life sciences, medicine or pharmacy and have at least five years of experience. Regulatory writers work to the guidance that governs each document.
Team roles
Sample work
Sample deliverables
Samples are published with sponsor agreement and redacted where requested.
Benefits
Benefits of a therapy-area lead for infectious disease and vaccine programmes
How matching writers to the therapy area supports your programme.
What you get
Packages
Quotes based on programme scope, not page count
Documents of the same length can involve very different work, so we do not price by word count. The free scoping read gives you a programme quote you can use for budgeting.
First
Scoping read
A free written assessment of what the programme needs, within two business days.
Then
A written scope
Documents, standards, named team and timeline, agreed before work starts.
Quoted
Per programme
One price for the agreed scope, with revisions within the agreed scope included rather than billed per round.
Infectious disease & vaccines FAQs
Common questions about infectious disease and vaccine projects
Yes. We assign a lead who has worked in infectious disease and vaccines and is familiar with correlates of protection. They can identify likely reviewer questions before drafting begins. If no one on our panel is a suitable match, we will tell you and decline the work.
It depends on your study design rather than the indication. In infectious disease and vaccines, this is typically: CONSORT 2025; STROBE for observational effectiveness; GRADE for synthesis; modelling reported to a transparent standard. We confirm the correct guideline during the free scoping read, because revising a completed report to a different guideline is much harder.
Immunogenicity results should not be presented as efficacy unless a correlate of protection has been established. Assessors check this first. We check for this on every infectious disease and vaccine programme before submission so it can be corrected early.
Payers and the public review results at the same time, so claims must be stated accurately and without overstatement. We flag this during the scoping read, while the evidence plan can still be adjusted.
Yes. A designated project lead coordinates the protocol, statistical analysis plan, clinical study report and publications to keep data interpretation and messaging consistent. Health-authority questions are answered by the writer of the document concerned.
We do not operate your pharmacovigilance system. We write the risk management plan and periodic reports, but case processing and reporting to authorities remain within your own PV system under your qualified person. We do not conduct trials, audit or certify GCP or GMP compliance, or claim authorship of your research. You remain the sponsor throughout.
Related Therapy Areas
Therapy areas often linked to infectious disease and vaccine programmes
Where a programme spans two therapy areas, we assign a lead for each area.
Other therapy areas
Discuss your infectious disease and vaccine project requirements
Tell us the indication and your timeline. The scoping read is free and takes two business days. You receive a written assessment of what the programme needs and who would lead it.